202 related articles for article (PubMed ID: 33425724)
1. The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis.
Wang Z; Shen H; Ma N; Li Q; Mao Y; Wang C; Xie L
Front Oncol; 2020; 10():572590. PubMed ID: 33425724
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
3. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Wang J; Zhang Y; Wei C; Gao X; Yuan P; Gan J; Li R; Liu Z; Wang T; Wang S; Liu J; Liu X
Front Oncol; 2020; 10():562504. PubMed ID: 33330031
[TBL] [Abstract][Full Text] [Related]
5. The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis.
Liu RJ; Hu Q; Li SY; Mao WP; Xu B; Chen M
Technol Cancer Res Treat; 2021; 20():15330338211035260. PubMed ID: 34313171
[TBL] [Abstract][Full Text] [Related]
6. The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis.
Wang Z; Shen H; Liang Z; Mao Y; Wang C; Xie L
Cancer Cell Int; 2020; 20():149. PubMed ID: 32390764
[TBL] [Abstract][Full Text] [Related]
7. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer.
Armstrong AJ; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Berry WR; Zhang T; Harrison MR; Lu C; Chen Y; Galletti G; Schonhoft JD; Scher HI; Wenstrup R; Tagawa ST; Antonarakis ES; George DJ; Halabi S
JCO Precis Oncol; 2020; 4():. PubMed ID: 33154984
[TBL] [Abstract][Full Text] [Related]
8. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and Predictive Value of Liquid Biopsy-Derived Androgen Receptor Variant 7 (AR-V7) in Prostate Cancer: A Systematic Review and Meta-Analysis.
Khan T; Becker TM; Scott KF; Descallar J; de Souza P; Chua W; Ma Y
Front Oncol; 2022; 12():868031. PubMed ID: 35372002
[TBL] [Abstract][Full Text] [Related]
10. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
[TBL] [Abstract][Full Text] [Related]
11. Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.
Qu F; Xie W; Nakabayashi M; Zhang H; Jeong SH; Wang X; Komura K; Sweeney CJ; Sartor O; Lee GM; Kantoff PW
Clin Cancer Res; 2017 Feb; 23(3):726-734. PubMed ID: 27489290
[TBL] [Abstract][Full Text] [Related]
12. Improved Androgen Receptor Splice Variant 7 Detection Using a Highly Sensitive Assay to Predict Resistance to Abiraterone or Enzalutamide in Metastatic Prostate Cancer Patients.
Maillet D; Allioli N; Peron J; Plesa A; Decaussin-Petrucci M; Tartas S; Ruffion A; Crouzet S; Rimokh R; Gillet PG; Freyer G; Vlaeminck-Guillem V
Eur Urol Oncol; 2021 Aug; 4(4):609-617. PubMed ID: 31676281
[TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological characteristics of androgen receptor splicing variant 7 (AR-V7) expression in patients with castration resistant prostate cancer: A systematic review and meta-analysis.
Li Q; Wang Z; Yi J; Shen H; Yang Z; Yan L; Xie L
Transl Oncol; 2021 Sep; 14(9):101145. PubMed ID: 34130051
[TBL] [Abstract][Full Text] [Related]
15. The association between androgen receptor splice variant 7 status and prognosis of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Zhou J; Liu R
Andrologia; 2020 Aug; 52(7):e13642. PubMed ID: 32401357
[TBL] [Abstract][Full Text] [Related]
16. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
17. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Antonarakis ES; Lu C; Wang H; Luber B; Nakazawa M; Roeser JC; Chen Y; Mohammad TA; Chen Y; Fedor HL; Lotan TL; Zheng Q; De Marzo AM; Isaacs JT; Isaacs WB; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
N Engl J Med; 2014 Sep; 371(11):1028-38. PubMed ID: 25184630
[TBL] [Abstract][Full Text] [Related]
18. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ
J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549
[TBL] [Abstract][Full Text] [Related]
19. Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials.
Rizzo A; Mollica V; Rosellini M; Marchetti A; Ricci AD; Fiorentino M; Battelli N; Santoni M; Massari F
Pathol Res Pract; 2021 Jun; 222():153440. PubMed ID: 33857854
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor splice variant 7 detected by immunohistochemical is an independent poor prognostic marker in men receiving adjuvant androgen-deprivation therapy after radical prostatectomy.
Ouyang W; Zhang Y; Long G; Sun G; Liu M; Li F; Yang C; Zeng X; Yang J; Yu X; Wang Z; Liu Z; Guan W; Hu Z; Wang S; Liu X; Li H; Xu H; Ye Z
Biomark Res; 2021 Mar; 9(1):23. PubMed ID: 33789757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
